Radiation Oncology/Prostate/Chemotherapy

From Wikibooks, the open-content textbooks collection

Jump to: navigation, search

Front Page: Radiation Oncology | RTOG Trials | Randomized Trials

Edit this

Prostate: Main Page | Prostate Overview | Screening and Prevention | Workup | Natural History | External Beam RT | IMRT | Androgen Suppression Therapy | Brachytherapy | Protons | Prostatectomy | Adjuvant RT after Prostatectomy | Salvage RT | Chemotherapy | Localized prostate cancer | Node Positive | Advanced disease | Recurrence after RT | Cryotherapy | RTOG Prostate Trials | Randomized Evidence

[edit] RT + Brachy + TAS + Docetaxel

Phase II Trial Preliminary

  • Protocol: 45 Gy pelvic EBRT + prostate brachytherapy + Docetaxel x 3 months + TAS x 2 years
  • Eligibility: T3/T4, or (GS 7 and PSA >10) or (GS 8-10 and PSA >7) without extrapelvic disease
  • Results: 36 patients, 20 months follow-up. No failures. Well tolerated.

[edit] RT + Hormones vs. RT + Hormones + Chemotherapy

  • RTOG 99-02 (2000-2004) -- RT + AS +/- TEE (taxol, estramustine, etoposide)
    • Randomized. Closed early due to thromobembolic events. 397 patients. High risk CaP (PSA 20-100 and GS >=7, or T2+, GS8, PSA <100). Neoadjuvant/concurrent and adjuvant AS + RT (2/2/2 TAA) +/- TEE Chemotherapy (taxol, estramustine, etoposide) x 4 cycles.
    • 2009 PMID 18990504 -- "Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02." (Rosenthal SA, Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):672-8. Epub 2008 Nov 5.)
      • Toxicity: AS 37% vs. AS + TEE 715 (SS), for hematological (SS), GI (SS), and trend GU (p=0.07). Three cases of MDS/AML in TEE arm
      • Conclusion: TEE associated with significantly increased toxicity during treatment
  • RTOG 05-21 (ongoing) - Prostate - A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT Vs AS and 3DCRT/IMRT Followed by Chemotherapy With Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer
    • Pts: 1) Gleason >=9 and PSA <= 150, Any T stage, 2) Gleason 8, PSA <20, T2 or higher, 3) Gleason 7-8, PSA 20-150, Any T stage. Clinically negative LN.
    • Arm 1: AS (LHRH agonist + oral antiandrogen) x 8 weeks, followed by RT to 72-75.6 Gy with concurrent AS. Continue LHRH for total of 24 months. Arm 2: Arm 1 plus 6 cycles of docetaxel (q3w) and daily prednisone 28 days after completion of RT.

[edit] Celecoxib

  • University of North Carolina - PMID 16609031 - "A phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy" (Pruthi RS, Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2172-7.)
    • 40 pts. Celecoxib (Celebrex) 400 mg/day. 36 of 40 (90%) had a slowing of PSA; 11 of 40 with decline in PSA, 8 with stable disease.
Retrieved from "http://en.wikibooks.org/wiki/Radiation_Oncology/Prostate/Chemotherapy"